Trial Search Results

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which radiation therapy regimen is more effective when given together with chemotherapy in treating patients with limited-stage small cell lung cancer. This randomized phase III trial is comparing different chest radiation therapy regimens to see how well they work in treating patients with limited-stage small cell lung cancer.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Alliance for Clinical Trials in Oncology

Collaborator: National Cancer Institute (NCI)

Intervention(s):

  • Radiation: Standard Radiation Dose Therapy
  • Drug: cisplatin
  • Drug: etoposide
  • Radiation: High Radiation Dose Therapy
  • Drug: carboplatin

Phase:

Phase 3

Eligibility


1. Documentation of Disease

      1. Histologically or cytologically documented small cell lung cancer (SCLC)

      2. Limited-stage disease patients with disease restricted to one hemithorax with
      regional lymph node metastases, including ipsilateral hilar, ipsilateral and
      contralateral mediastinal, and ipsilateral supraclavicular lymph nodes

         - Patients with disease involvement of the contralateral hilar or
         supraclavicular lymph nodes are not eligible

         - Patients with pleural effusions that are visible on plain chest radiographs,
         whether cytologically positive or not are not eligible unless they have a
         negative thoracentesis

         - Patients with cytologically positive pleural or pericardial fluid,
         regardless of the appearance on plain x-ray are not eligible

   2. Measurable disease - Patients must have measurable disease, which includes lesions
   that can be accurately measured in at least one dimension (longest diameter to be
   recorded) as ≥ 2 cm with conventional techniques OR ≥ 1 cm by spiral CT scan

   3. Prior Treatment

      1. Patients may have received one and only one cycle of chemotherapy prior to
      enrolling on CALGB 30610, which must have included carboplatin or cisplatin and
      etoposide.

      2. If a patient has had one cycle of cisplatin or carboplatin/etoposide prior to
      registration, the patient must have had all of it prior to registration tests as
      outlined in the protocol and prior to starting their first cycle of chemotherapy.

      3. Additionally, these patients also must have met all of the eligibility criteria
      in the protocol prior to receiving the first cycle of chemotherapy.

      4. Registration to CALGB 30610 must take place within 14-21 days after the start of
      the non-protocol therapy.

      5. Failing to do all of the above will make the patient NOT eligible for CALGB
      30610.

      6. No prior radiotherapy or chemotherapy (except for the chemotherapy described in
      the bullet above) for SCLC

      7. No prior mediastinal or thoracic radiotherapy

      8. Patients with complete surgical resection of disease are not eligible

   4. Age Requirement ≥ 18 years of age

   5. ECOG Performance Status 0-2

   6. Non-pregnant and non-nursing - No patients that are known to be pregnant or nursing

   7. Required Initial Laboratory Values

      1. Granulocytes ≥ 1,500/µl

      2. Platelet count ≥ 100,000/µl

      3. Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

      4. AST (SGOT) ≤ 2.0 times ULN

      5. Serum creatinine ≤ 1.5 times ULN OR Calculated creatinine clearance ≥ 70 mL/min

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Madelyn Kissel
650-497-8966
Recruiting